Tower Research Capital LLC (Trc) Aerovate Therapeutics, Inc. Transaction History
Tower Research Capital LLC (Trc)
- $4.87 Billion
- Q4 2024
A detailed history of Tower Research Capital LLC (Trc) transactions in Aerovate Therapeutics, Inc. stock. As of the latest transaction made, Tower Research Capital LLC (Trc) holds 3,866 shares of AVTE stock, worth $9,162. This represents 0.0% of its overall portfolio holdings.
Number of Shares
3,866
Previous 4,881
20.79%
Holding current value
$9,162
Previous $10,000
-0.0%
% of portfolio
0.0%
Previous 0.0%
Shares
15 transactions
Others Institutions Holding AVTE
# of Institutions
83Shares Held
30.7MCall Options Held
186KPut Options Held
269K-
Ra Capital Management, L.P. Boston, MA9.19MShares$21.8 Million0.39% of portfolio
-
Sofinnova Investments, Inc. Menlo Park, CA3.76MShares$8.91 Million0.81% of portfolio
-
Tcg Crossover Management, LLC Palo Alto, CA2.24MShares$5.31 Million0.97% of portfolio
-
Atlas Venture Life Science Advisors, LLC1.8MShares$4.26 Million0.79% of portfolio
-
Braidwell LP Stamford, CT1.44MShares$3.41 Million0.21% of portfolio
About Aerovate Therapeutics, Inc.
- Ticker AVTE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 24,448,100
- Market Cap $57.9M
- Description
- Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. The company focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which ...